P & G’s probiotic supplement now available nationwide
CINCINNATI Procter & Gamble on Thursday officially launched its Align daily probiotic supplement.
Once exclusively available online and through special order from pharmacists, Align will now be available on store shelves across the United States in spring 2009.
Align contains the probiotic strain, Bifantis (Bifidobacterium infantis 35624), which has been clinically proven to help promote the balance of healthy bacteria in the digestive system and to help build and maintain an ongoing natural defense against five signs of episodic digestive imbalance – constipation, diarrhea, urgency, gas and bloating.
“With continued professional and consumer accolades, we are extremely enthusiastic for the national launch of Align and further building our consumer health care business”, stated Mauricio Troncoso, P&G’s director, global digestive wellness. “Broadened availability of Align is on strategy with P&G’s efforts to focus on our consumer health care brands.”
Digestive health is expected to be a key health trend in 2009, P&G noted, and the probiotics category is leading the charge. Align helps naturally defend against digestive imbalance, with ongoing protection from episodic digestive upsets. The product has already received overwhelming support via online sales and in test markets, as well as professional support through its efficacy in clinical practice.
“We know consumers with episodic digestive problems are looking for real solutions, and Align is a clinically proven option,” stated Tom Kuhn, Align brand manager. “Because Align is grounded in real science and meets a real consumer health need, we expect it to become a cornerstone brand in our personal healthcare portfolio.”
As Procter & Gamble prepares to rollout Align nationally, the product’s packaging will be changing from a yellow and blue box to a green and white box with a new logo design that includes revised information to help consumers understand how Align can help provide a balancing defense against episodic digestive issues.
The new packaging also has educational information on the box to help consumers confidently select the product while keeping up with their supplement regimen through tracking tools and reminders.
Bayer Consumer Care praises USPSTF’s recommendation of broader use of aspirin
MORRISTOWN, N.J. Bayer Consumer Care on Tuesday commended the U.S. Preventive Services Task Force’s recent support of broader use of aspirin in the prevention of heart attack and stroke.
“[Tuesday’s] recommendations add support for broader appropriate uses of aspirin and do not affect the already [Food and Drug Administration]-approved indications for prevention of recurrent heart attack and stroke, as well as reduction of the risk of death when taken during a suspected heart attack,” Bayer stated. “Further, it’s important that those on doctor-recommended aspirin treatment regimens do not stop taking aspirin without consulting with their doctor as research shows that aspirin withdrawal actually puts patients at higher risk for a cardiovascular event.”
The new recommendations provide more specific guidance on aspirin use, providing clarity on maximizing benefits and minimizing risk, Bayer suggested. To help increase awareness around appropriate use of aspirin as a prophylactic to heart disease, Bayer is introducing “Is Aspirin Right For Me?” — a downloadable discussion guide available at http://www.wonderdrug.com/ to help consumers have meaningful conversations with their healthcare providers to together determine if aspirin is right for them.
“Bayer applauds the USPSTF for today’s important announcement,” stated Wes Cetnarowski, SVP global research and development at Bayer Healthcare. “These recommendations are consistent with our ongoing commitment to advancing appropriate aspirin use to reduce the personal and public health impact of cardiovascular disease.”
The USPSTF granted its highest level of evidence rating encouraging the use of low-dose aspirin in men over 45 and women over 55 to prevent first heart attack and ischemic stroke respectively, when the benefits outweigh the risks. The guidance specific to women is based on results from the Women’s Health Study.
As stated in the Annals of Internal Medicine accompanying editorial, Aspirin for Prevention and Treatment of Cardiovascular Disease, “in women older than 65 years, the WHS did demonstrate a clear 26% reduction in [myocardial infarction]: the same risk reduction as occurred in primary prevention trials of aspirin in men.”
In addition, the new recommendations advise caution with respect to aspirin use in men and women 80 and above.
LifeScan, Apple demonstrate prototype diabetes management software
MILPITAS, Calif. Johnson & Johnson’s LifeScan on Tuesday demonstrated a prototype diabetes management software application, integrating the company’s OneTouch blood glucose meters with the Apple iPhone and iPod touch products. LifeScan was one of a handful of companies invited by Apple to develop and preview innovative new applications at Apple’s iPhone OS 3.0 software event, the company stated.
Using a modified OneTouch Meter, the prototype application demonstrated transmission of a blood glucose test result to the Apple iPhone. Once on the iPhone, test results were available for integration with other information in a series of user-friendly graphics, including the user’s level of glucose control over time relative to targets established with his or her healthcare professional.
The application also will include a customizable food database to help users determine the amount of carbohydrates consumed during meals. Future applications also may include the capability for users to calculate a bolus insulin dose based on the last glucose result and the number of carbohydrates that will be consumed.
The new OneTouch/iPhone application is in the early stages of development, the company noted.